Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

Summary

Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive, operator-dependent, and limited in their ability to detect early-stage lesions. To address this clinical need, the SYNERGY study seeks to develop a non-invasive, blood-based biomarker assay that integrates cell-free microRNAs (cf-miRNAs) and exosomal microRNAs (exo-miRNAs) to detect ESCC at an early and potentially curable stage. This multicenter translational study includes discovery, training, and validation phases using preoperative plasma or serum samples. By combining the tumor specificity of exosomal miRNAs with the systemic sensitivity of cf-miRNAs, SYNERGY aims to construct a robust diagnostic model with high sensitivity and specificity for early ESCC detection.

Eligibility

Inclusion Criteria:

* Adults age 18 to 90 years
* Histologically confirmed esophageal squamous cell carcinoma
* No prior systemic therapy before sample collection
* For control groups: absence of malignant disease

Exclusion Criteria:

* Lack of informed consent
* Inadequate sample volume or RNA quality
* Prior cancer within 5 years (except localized cancers)
* Active systemic inflammation that may alter circulating RNA profiles

Conditions2

Locations1 site

Browse More Trials